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EDITORIAL REVIEW
Endopeptidase-24. 11 and its inhibitors: Potential therapeutic
agents for edematous disorders and hypertension
Endopeptidase-24. 11 (E-24. 11) is a zinc-dependent cell-sur-
face enzyme. First characterized as a peptidase of the brush
border of the renal proximal tubule and purified from rabbit
kidneys [1, 2], it has since been identified immunologically in a
number of tissues, including other brush borders (intestine,
placenta, choroid plexus), gonads, epithelia of the genital
tracts, peripheral nerves and brain [3—141. It therefore has a
wide, but by no means ubiquitous, tissue distribution and is
capable of hydrolyzing many natural and synthetic peptide
substrates, such as neuropeptides, the natriuretic peptides and
the endothelins [15—25], attributes that suggest that it may have
multiple physiological functions. Therapeutic interest first fo-
cused on its action in the brain, where E-24. 11 ("enkephali-
nase") had been shown to participate in the metabolism of
endogenous opioid peptides, such as the enkephalins. It was
reasoned that inhibitors of the enzyme might be useful as
analgesics by increasing endogenous enkephalin levels, but so
far no clinically useful compounds have emerged. More re-
cently, attention has been given to the role of this enzyme in
clearing peptides with natriuretic actions, in particular atrial
and brain natriuretic peptide (ANP and BNP). The demonstra-
tion that both ANP and BNP are good substrates for E-24.ll
[22, 26—28] has raised the possibility that E-24. 11 inhibitors
might be used to potentiate their natriuretic and hypotensive
actions and have a place in the management of heart failure and
hypertension. This review will focus on the renal and cardio-
vascular pharmacology of E-24. 11 inhibitors and their potential
use as therapeutic agents.
Biochemistry of E-24.11
Molecularproperties
E-24.l1 is an ectoenzyme, implying that it is located at the
cell-surface, with the bulk of the enzyme, including the zinc-
containing active site, at the external surface [8]. Its action is
therefore directed at peptides in the extracellular milieu which
come within its vicinity. It is a 90 kDa glycoprotein, usually
dimeric and firmly anchored in the plasma membrane. The
primary structure has been elucidated by cDNA cloning for the
human, rabbit and rat enzymes [29—31]. These studies have
shown it to be a type II membrane protein anchored near the
N-terminus.
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Tissue and cellular distribution
Although found in a number of tissues, some species varia-
tion is clear: for example pig lymph nodes are a major source of
E-24.ll, second only to the kidney [41, but in other species,
including human, the enzyme is barely detectable in lymph
nodes. Moreover, in the pig kidney it is located primarily in the
microvilli of the proximal tubule [3], but significantly (in rela-
tion to ANP and BNP actions) in some other species including
rabbit and human, it is also present in glomeruli [9, 32]. E-24. 11
is less abundant in endothelial cells than angiotensin converting
enzyme (ACE) but recently the presence of the enzyme has
been demonstrated in these cells using measurements of en-
zyme activity and the techniques of reverse transcription-
polymerase chain reaction and immunocytochemistry [33—35].
The enzyme is also present in blood: on the surface of neutro-
phils [36, 37] and on leukemic cells in most cases of common
acute lymphoblastic leukemia (CALL), that is, it is identical
with CD-b (CALLA).
We are still largely ignorant of the target of the target
molecules for the peptidase at all these diverse sites, although in
the CNS there is some evidence that tachykinins [38—40] and
enkephalins [41] may be inactivated; elsewhere the target
peptides are a matter of speculation.
Substrate specificity
The primary specificity of E-24. 11 is to hydrolyze peptide
bonds on the amino side of hydrophobic amino acid residues,
similar to that of the microbial enzyme, thermolysin [1]. How-
ever, the nature of nearby residues on either side of the scissile
bond and conformational factors greatly influence the efficiency
of hydrolysis as shown in Figure 1. In kinetic terms (kat/Km
ratio) substance P is hydrolyzed by the pig enzyme 100 times
better than LHRH, though both contain a hydrolyzable Gly-
Leu bond [17]. Simple peptides (for example, less than 30
residues) are preferred: the B-chain of insulin is hydrolyzed, but
the intact insulin molecule is wholly resistant [21]. Very slow
hydrolysis of interleukin-1f3 has been observed (Kenny, unpub-
lished observation), but the smaller, 50-residue peptide, trans-
forming growth factor-a, resists attack [43]. In general, most
simple biological peptides are substrates and among the battery
of cell-surface peptidases (including ACE and other exopeptid-
ases) present on, say, the pig renal microvillar membrane,
E-24. 11 is the enzyme that initiates the attack. This has been
shown in vitro for many peptides including ANP, BNP, sub-
stance P, bradykinin, the angiotensins and oxytocin [21, 22, 28].
One must be cautious in extrapolating such data to the in vivo
metabolism of the same peptides, where peptide concentrations
and accessibility of the enzyme may be crucial factors.
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Substance P (deamidated)
Neurokinin A
Substance P
[Met5l enkephalin-Arg6-Phe7
[Nor Leul] Substance P
Physalemin
Bradykinin
[D-A1a2, Leu5] enkephalin
Chemotactic peptide
[Met5] enkephalin-Arg6
[Leu5] enkephahn
[Met5] enkephalin
[Leu5] enkephahn-Arg6 I
CCK-8 suiphated I
CCK-8 I
Dynorphin (1—9) I
[Leu5l enkephalin (isostere) I
Neurotensin I
[D-A1a2, Met5] enkephalinamide I
DeMeC7
(D-A1a2, Leu5l enkephalinamide I
[Leu5] enkephalinamide
LH-RH
Fig. 1. Relative efficiency of hydrolysis of some biologically active peptides by purfled pig E-24.l1. For each peptide Km and keat were determined
and the ratio kcat/Km expressed relative to that of [Leu5] enkephalin (for which the values were, Km = 86 tLM, kcat = 3781 min1). Data are from
[17, 19, 1431.
Inhibitors
Phosphoramidon, a natural product from Streptomyces ta-
nashiensis, is a specific inhibitor of thermolysin [44] and, given
the similarity of the active site of this enzyme to that of E-24. 11,
it was not surprising that it inhibited the latter efficiently (Ki =
2 nM) [45]. The two essential structural features of this class of
inhibitor are a dipeptide (or analogue) with a hydrophobic
side-chain at P1 and an anionic group which is linked to (or
replaces) the amino group and coordinates the active site of
Zn2. In phosphoramidon these criteria are met by a phosphi-
nyl-Leu-Trp moiety. Thiorphan was the first synthetic inhibitor,
designed by Roques et al [46] before the identity of "enkepha-
linase" with E-24.ll had been shown; here a thiol group
coordinates the metal and the dipeptide is an analogue of
Phe-Gly. Many other effective compounds have now been
synthesized in which carboxylate or hydroxamate groups effect
the coordination to the zinc atom. Examples of all four types of
inhibitor are shown in Table 1.
Natriuretic peptides and their metabolism
A decade has now passed since ANP was first isolated from
cardiac atria and its amino acid sequence determined [47, 48].
In that time other structurally related peptides with natriuretic-
diuretic and vasorelaxant activities have been found: brain
natriuretic peptide (BNP), C-natriuretic peptide (CNP) and
urodilatin. Derived from separate precursor molecules (except
for urodilatin, which is identical to cs-hANP with four additional
residues at the N-terminus) they have a disulphide-linked loop
of 17 amino acids in common, the integrity of which is essential
for biological activity. In humans, the important active forms
are (Fig. 2): a-hANP (28 residues) [49], hBNP-32 (32 residues)
[42, 50], hCNP-22 (22 residues [51, 52] but another 53 residues
form has also been reported in brain [53]) and urodilatin (32
residues) [54, 55]. Collectively these peptides are believed to
participate in the regulation of sodium and water homeostasis
and blood pressure, but the relative contribution of each
peptide is not yet clear. Studies have revealed differences
between them in tissue distribution. ANP is most abundant in
cardiac atria but is also found in several other tissues including
the brain, adrenal gland and testis [56]. BNP is present in brain
and heart; in the heart, the highest concentration is found in the
atria, but because of its larger mass, a greater quantity is
present in the ventricles [57]. CNP is largely confined to the
nervous system, with only small amounts in intestine and
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Table 1. Some inhibitors of endopeptidase 24.11
Class Name Ki nM Notes
Phosphinyl Phosphoramidon 2 Natural product
Thiol Thiorphan
Retrothiorphan
Sinorphan
Acetorphan
SQ 29072
Q 28133
2.5
2.3
2 Pro-drug
Pro-drug
Mixed inhibitor
(E-24.ll &
ACE)
SQ 28603
RB 101 1 Mixed inhibitor
(E-24.ll &
aminopeptidase)
Carboxylate SCH 39370
SCH 34826
SCH 32615
UK 79300
UK 73967
UK 69578
11
20
14
52
Pro-drug
Active form of
SCH 34826
Candoxatril (pro-
drug)
Candoxatrilat
(active form)
Unresolved
enantiomers
Hydroxamate Kelatorphan
RB 45
1.7
0.03
Mixed inhibitor
(E-24.11 &
aminopeptidase)
Isomer of
kelatorphan
The class refers to the chemical nature of the group coordinating the
zinc at the active site of E-24. 11. Pro-drugs are derivatives, esterified or
acetylated, so that hydrolysis in the intestine is necessary to liberate the
active inhibitory form. Reviewed in 1144, 145].
kidney [52, 58], although CNP, unlike ANP or BNP, has been
demonstrated in vascular endothelial cells by immunocyto-
chemistry [59]. Urodilatin was first isolated from human urine
and has been postulated to be produced and act locally within
the kidney [55].
To date only ANP and BNP have been clearly demonstrated
in plasma. In health, the plasma levels of ANP are 6- to 17-fold
greater than BNP, but in cardiac failure BNP els rise to
match or exceed ANP levels [60—62]. The half-liJ i circulating
ANP is very short with estimates ranging froi to three
minutes [63—65], and clearance by passage throt, e vascular
beds of g, liver, kidney and intestine has bee ionstrated
[66]. It been reported that 80% of ANP i ioved by a
single p -. ge through the kidney [67]. The hab : of BNP in
plasma . proximately twice that of ANP [6'. '9], but the
tissue s: f its degradation have been less extnsively stud-
ied.
The o vation that ANP is hydrolyzed by E-24. 11 led to the
proposal that this is an important mechanism of ANP clearance
in vivo. E-24. 11 hydrolyzes a-hANP rapidly with the initial
attack at the Cys7-Phe8 bond, thus opening the ring and leading
to inactivation. This point of attack is important in interpreting
immunoassays, since some antisera to intact a-hANP may also
recognize the ring-opened, inactive form. Other susceptible
bonds within the ring and in the tail are cleaved subsequently.
In contrast, the initial attack on human BNP is in the N-terminal
sequence and not within the ring (Bourne and Kenny, unpub-
lished observations). It remains to be shown whether cleavage
of this bond inactivates BNP. Although urodilatin has been
reported to be resistant to hydrolysis by dog kidney cortex
membranes [70], it is hydrolyzed by E-24.ll at about half the
rate of ANP (Kenny, unpublished observation). Neither ANP
or BNP is hydrolyzed by ACE [22, 28].
A second mechanism of ANP clearance has also been pro-
posed, namely receptor-mediated endocytosis [71]. ANP recep-
tors have been identified in many tissues, including vascular
smooth muscle, renal glomerulus, adrenal zona glomerulosa
cells, choroid plexus and brain [72—76]. One receptor type is a
transmembrane protein capable of binding ANP and BNP at the
extracytoplasmic domain and of generating cyclic GMP at the
cytoplasmic domain [77, 78]. This class (also known as ANP-
Ri) is therefore biologically active and exists as two subtypes,
A and B (Fig. 3). ANP shows the greatest potency for stimula-
tion of the A-receptor; BNP also activates this receptor, but a
tenfold higher concentration is required [79]. CNP selectively
activates the B-receptor, with an affinity at least 50-fold greater
than either ANP or BNP [80].
Another type, the C-receptor (also known as ANP-R2), has
been recognized which lacks the cytoplasmic guanylate cyclase
domain and is thought by many to be biologically "silent" [71,
81]. While there is some evidence that it is coupled to adenylate
cyclase, in that binding of ANP (at nM concentrations) to the
C-receptor in rat platelets inhibits cyclic AMP formation [82], a
widely held view is that this receptor has a clearance role.
C-receptors out-number the other types [83, 84] and unlike A
and B receptors, which display rigorous criteria for ligand
binding, they are much less demanding as regards structure,
even tolerating D-amino acid substitutions [85]. Consistent with
a clearance role, C-receptors have been shown to internalize
ANP in vascular smooth muscle cultures [86, 87]. Furthermore,
the specific C-receptor ligand, C-ANP (4—23) (Fig. 2), has been
shown to cause an increase in plasma ANP levels in vivo [71].
In attempting to assess the roles of the C-receptor and E-24. 11
in the metabolism of these peptides, it should be noted that the
Kd for receptor binding of ANP has been reported to be in the
range 60 M to 2 nM [88, 89], while estimates of the Km for
hydrolysis of natriuretic peptides by E-24. 11 are between 10
and 100 /LM [90] (Bourne and Kenny, unpublished observa-
tions). However, the relative capacities of the two clearance
systems must also be considered, and recent studies indicate
that both C-receptors and E-24. 11 modulate plasma ANP in the
physiological range.
Role of E-24.11 in the metabolism of ANP and other natriuretic
peptides in vivo
Given the relatively broad spectrum of substrate specificity of
E-24. 11, it is plausible that inhibitors of the enzyme will
influence the metabolism of a number of peptides in vivo. In the
context of the kidney and the regulation of vascular tone, the
major peptides of interest are the atrial natriuretic peptides,
kinins, the endothelins and the gut-brain peptides. Of these only
ANP has been studied systematically.
If E-24. 11 represents an important pathway of ANP metabo-
lism in vivo, then E-24. ii inhibitors should reduce clearance of
the peptide and increase circulating levels. In practice, when
basal plasma ANP levels are in or near the "physiological"
range, the changes observed during E-24.ll inhibition have
'eptide Receptors Signal
ANP(
A _____
cGMPf
BNP f—.- c... C - - (G-protein) cAMP
CNP/C B _____ cGMPt
Cell membrane
Outside cell Inside cell
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Peptide
a-hANP-28
Amino acid sequence
SLRRSSCFGGRNDRIGAQSGLGCNSFRY
C—ANP 4-23 RSSCFGGRIDRIGAC
SC4 6542 SSCGRMDRIGSGLGCNSFRY
tJrodilatiri-32 TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY
hBNP- 32 S PKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
hCNP-22 GLSKGCFGLKLDRIGSMSGLGC
Fig. 2. Sequences of human natriuretic
peptides and two synthetic analogues;
highlighted are amino acid sequences within
the ring common to this group.
Fig. 3. interactions between natriuretic peptides and their receptors.
The A and B receptors (ANP RI type) are ganylate cyclase-linked.
The C receptor (ANP R2 type, clearance receptor) has a smaller
intracellular domain, is not linked to cGMP production, but has been
reported to inhibit adenylate cyclase, reducing intracellular cAMP.
been small, if detectable at all. While single oral doses of
acetorphan (100 or 300 mg) have been reported to increase
plasma ANP levels sixfold over placebo in healthy volunteers
[92], similar studies with candoxatril (25 to 100 mg) and SCH
34826 (400 to 1600 mg) have found little (< twofold) [911 or no
significant change [93, 94, 122]. A rise in circulating ANP levels
is more often found when basal plasma levels are already
elevated, due to disease or following infusion of exogenous
peptide. Thus, Trapani et a! report a twofold increase in plas-
ma ANP levels when thiorphan (30 mg kg ') was given to
anesthetized rats receiving an infusion of ANP (330
ng kg . min1) [95]. Two- to threefold rises have been
observed with sinorphan (10 to 100 mg) in patients with con-
gestive cardiac failure [96, 97] and hepatic cirrhosis [98].
It is likely that the attenuated plasma AMP response to
E-24. 11 inhibitors, most obvious at low plasma levels, is due to
a compensatory action by C-receptors. Comparative studies
have been made of the effect of E-24. 11 inhibitors and the
specific C-receptor ligand, C-ANP (4—23), on the pharmacoki-
netics of 1251-ANP in anesthetized rats [99]. The E-24.11
inhibitor SCH 39370 reduced clearance without altering half-life
or volume of distribution and increased area-under-plasma-
concentration curve (AUC) fourfold. Similar observations have
been made with candoxatrilat [100]. C-ANP (4—23), on the other
hand, decreased both clearance and volume of distribution,
leading to a fourfold increase in half-life and a sevenfold rise in
AUC. These studies suggest that the receptor-mediated path-
way has the greater capacity for clearing plasma ANP. It is
likely that E-24. 11 and C-receptors act in concert to regulate
plasma ANP levels and that the effects of inhibiting one can be
offset by the activity of the other. In support of this concept,
combined administration of C-AMP (4—23) and SCH 39370
produced a 7.5-fold increase in half-life and a 15-fold rise in
AUC, a larger response than the sum of their individual effects
[99]. However, the capacity of, for example, the receptor-
mediated pathway to buffer the response to E-24. 11 inhibition is
going to be greatest at low plasma AMP levels and become more
saturated at higher levels. Hence an increase in ANP levels is a
more consistent finding when E-24. 11 inhibitors are given in the
setting of elevated basal plasma levels.
Further evidence that E-24. 11 participates in the metabolism
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of ANP in vivo is provided by studies in which urinary ANP
levels have been measured. The levels of ANP found in urine
test the limits of detection of most radioimmunoassays, even if
plasma ANP levels are elevated to pharmacological levels.
Presumably E-24. 11 in the brush border of the proximal tubule
is efficient enough to degrade the quantities of ANP that are
filtered at the glomerulus. Administration of an E-24. 11 inhibi-
tor leads to a marked increase in the appearance of immunore-
active ANP in the urine [101, 1021 (Fig. 4) and HPLC analysis
demonstrates that the majority of the immunoreactive material
co-elutes with the biologically active species, ANP-28 [1031.
It is tempting to speculate that E-24. 11 has a greater role in
the clearance of BNP as the binding of this peptide to C-recep-
tors has been calculated to be about 7% of that of ANP [611.
Oral dosing with candoxatril has been shown to elevate plasma
BNP levels in patients with cardiac failure [104] but the contri-
bution of E-24. 11 to inactivating BNP in vivo is presently
unknown. Similarly, the clearance pathway(s) for CNP have
not been defined. Although urodilatin has been reported to be
resistant to degradation by dog renal cortical membranes [70]
(but see comment above), studies in the A-V fistula rat suggest
that the effects of urodilatin can be increased by E-24. 11
inhibition [Note added in proof (a)]. Outside this natriuretic
family, Ura, Carretero and Erdos [20] have demonstrated that
E-24. 11 also participates in the catabolism of kinins. These
authors infused phosphoramidon into anesthetized rats and
observed a 77% decrease in total urinary kininase activity and a
73% increase in urinary kinin excretion. Clearly these observa-
tions are relevant to the interpretation of the effects of E-24. 11
inhibitors in animals and humans.
Effects of E-24.11 inhibition on sodium excretion and blood
pressure in animals
The first demonstration that inhibition of E-24. 11 can influ-
ence urinary sodium excretion was provided by Ura, Carretero
and Erdos [20]. These authors infused phosphoramidon (330
kg hr) into anesthetized rats and observed a small
increase in urine flow (15%) and sodium excretion (37%). No
effects were seen on blood pressure or glomerular filtration rate
(GFR), and the renal response was attributed to inhibition of
intrarenal kinin metabolism.
With the knowledge that ANP is also a substrate for E-24. 11
[22], interest in the renal and cardiovascular effects of E-24. 11
inhibition has gathered momentum. Co-administration of
E-24. 11 inhibitor and ANP potentiates the renal response to the
peptide [95, 103, 105]. Thus, Trapani et al [95] gave a pharma-
cological dose of ANP (330 ng kg' min 1) to anesthetized
rats, elevating plasma levels to around 6 ng ml1 and inducing
a marked increase in sodium excretion; bolus injection of
thiorphan (30 mg kg ') at the start of the ANP infusion
produced a further twofold rise in plasma levels and doubled the
peak natriuresis. Interestingly, thiorphan did not enhance the
hypotensive response to ANP, a finding which has been con-
firmed in other studies in normotensive rats [106]. However,
E-24. 11 inhibition has been reported to increase the hypoten-
sive effect of ANP in the spontaneously hypertensive rats
(SHR). Sybertz et al [103] found that pretreatment with SCH
39370 (30 mg kg1 s.c.) potentiated the hypotensive response
to ANP 30 xg kg_I (—38 6 compared to —13 3 mm Hg in
controls) but not ANP 1 jxg kg'. Seymour, Fennell and
Swerdel [105] observed that SQ 29072 (100 xmol kg i.v.)
increased and prolonged the fall in blood pressure produced by
bolus injection of ANP, although again the effect was most
convincing with the highest dose of ANP used (30 nmol kg').
Given alone to healthy rats, the response to E-24. 11 inhibi-
tors is strongly influenced by their hydration status, an impor-
tant determinant of endogenous ANP levels. Thus, thiorphan
(30 mg kg) has little or no effect on plasma ANP levels,
blood pressure or sodium excretion when given to euvolemic
rats receiving saline at a rate of 33 d min1 [95]. With a higher
rate of saline infusion (333 jxl min1), Shepperson et al [1071
reported that UK 69578 (3 mg kg ') produced a threefold
increase in sodium excretion over that seen with vehicle alone.
Similarly, Bralet et al [108] found that acetorphan (10
mg kg 1) given orally to conscious rats nearly doubled the
effect of volume expansion (by injection of Ringer solution, 30
ml kg) on sodium excretion in the two hours following the
stimulus.
Logically these studies have been extended to animal models
of disease associated with raised endogenous plasma ANP
levels. Lafferty et al [109] examined the effects of two E-24.1l
inhibitors in rats with reduced renal mass (5/6 nephrectomy). In
this model of chronic extracellular volume expansion "basal"
plasma ANP levels were elevated fourfold above the control
group. Phosphoramidon (500 g kg' min' for 1 mm; then
250 kg' . min 1) induced a further threefold rise in plasma
ANP levels and a fivefold increase in sodium excretion. This
effect was accompanied by a fivefold rise in urinary cyclic GMP
excretion. A similar response was obtained with thiorphan.
In cardiac failure, plasma ANP levels are elevated in propor-
tion to the degree of cardiac decompensation. While reduced
clearance may contribute to the raised levels, there is ample
evidence for increased synthesis and secretion of the peptide.
Paradoxically, there is also resistance to the renal and hypoten-
sive activity of ANP in this condition [101, 110]; for example, in
rats with aorto-venocaval fistulae (a model of high-output heart
failure) 7 to 14 days post-surgery, the natriuretic response to
200
1
4rhiorphan,
0
Ii) **
a) .
100
* *
*
C
*
0
15 30 45 60 75 90 105 120
Time, minutes
Fig. 4. Effect of the E-24.11 inhibitor, thiorphan, on urinary excretion
of ANP in sham-operated (El) and aorto-caval (A-V) fistula (•) rats.
ANP was measured by ELISA [101]. < 0.05, < 0.01.
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increasing doses of ANP was only half that seen in sham-
operated animals [101]. This resistance is mediated by several
factors, such as increased activity of the renin-angiotensin
system, increased renal sympathetic nerve activity and down-
regulation of ANP receptors. In contrast to the effect of infusing
ANP, thiorphan (0.5 mg kg' . min) induced a brisk four-
fold increase in urinary sodium excretion in this model [101].
This response was produced without a fall in blood pressure.
This surprising though important finding has been confirmed in
other models of heart failure. In anesthetized dogs with conges-
tive cardiac failure induced by eight days of rapid right ventric-
ular pacing, SQ 28,603 (30 and 60 mg kg—') produced dose-
dependent (4- and 8-fold, respectively) rises in sodium
excretion [1101. The natnuresis in these animals was produced
without an accompanying rise in GFR or renal blood flow, but
was associated with an increase in fractional lithium excretion,
suggesting a renal tubule effect. More recently these authors
have reported that the response to SQ 28,603 can be enhanced
in this animal model by pretreatment with an ACE inhibitor
[111].
Several groups have studied the effects of E-24. 11 inhibition
in the SHR and deoxycorticosterone acetate (DOCA)-salt hy-
pertensive rat [102, 103, 105, 112—119]. Acute dosing with these
inhibitors appears to elicit a greater response in the DOCA-salt
rat than the SHR. Indeed the effect in the SHR in some studies
has been very disappointing [103, 115, 119]. Thiorphan (in doses
up to 30 mg kg_I i.v.) does not reduce blood pressure in the
conscious [115] or anesthetized [102] SHR, but a transient
threefold natriuresis has been reported in the first 60 minutes
following administration in the anesthetized preparation [102].
Subcutaneous administration of SCH 39370 (0.3 to 30
mg kg I) produced a dose-dependent reduction of arterial
blood pressure in conscious DOCA-salt rats; for example, with
30 mg kg_i a fall of approximately 36 mm Hg was observed
two hours after the injection which was sustained for the four
hour duration of the study [103]. In contrast, 30 mg kg1 S.C.
did not reduce blood pressure in the SHR. In a subsequent
study, SCH 34826 90 mg kg s.c. reduced mean arterial
pressure by 35 12 mm Hg in conscious DOCA-salt rats and
doubled urine volume and sodium excretion in the three hour
period following the injection; again, the same dose did not
affect blood pressure acutely in the SHR [119]. SQ 29,072 given
as 100 or 300 mol kg1 i.v. led to falls in mean arteia1 blood
pressure of 36 7 and 41 8 mm Hg, respectively, in the
conscious DOCA-salt rat compared to 11 24 and 31 5 mm
Hg in the SHR [112]; a modest but significant natriuresis was
also seen in the DOCA-salt group in the first two hours after
administration but not in the SHR. It is tempting to suggest that
the greater sensitivity of DOCA-salt rats to the effects of
E-24. 11 inhibition is due to higher circulating levels of ANP in
this model. Plasma ANP levels have been reported to be
elevated twofold in the SHR, but some authors have found
levels in the normal range. In their experience, Seymour et al
[112] have found no difference in basal levels between DOCA-
salt and SHR. Rather, these authors (and others [119]) note that
the DOCA-salt rat is more sensitive than the SHR to the
hypotensive effects of ANP, implying a difference in tissue
responsiveness to the peptide.
Two studies have examined the hypotensive response to
repeated administration of an inhibitor. Sybertz et al [119] gave
SCH 34826 90 mg kg1 s.c. twice daily for five days to SHRs
with indwelling arterial catheters. A modest but significant fall
in blood pressure was recorded on day 3 and sustained for the
remainder of the study. In the DOCA-salt rat, infusion of SQ
28,603 (3.7 mo1 kg' min') for six hours caused a sus-
tained fall in mean arterial pressure (ca. 40 mm Hg) during the
period of treatment, followed by a gradual return of bLood
pressure to baseline levels over the next 12 hours [113]. A
similar hypotensive response was observed when the infusion
was recommenced in the same rats the following day. In
contrast to the effect on blood pressure, a transient natriuresis
was measured in the first hour of the first treatment period and
not repeated during the second exposure to the compound,
indicating other mechanisms in addition to natriuresis contrib-
ute to the fall in blood pressure.
The hypotensive response to E-241 1 inhibition in the SHR
(but not the DOCA-salt rat) may be augmented by combination
with an ACE inhibitor [Note added in proof (b)]. Another
strategy is to combine the E-241 1 inhibitor with a C-receptor
ligand, such as C-ANP (4—23) or SC 46542 [114—117]. Given
alone, bolus injection of thiorphan (30 mg kg 1) or a brief (20
to 40 mm) infusion of SC 46542 (16 g kgt min) had no
effect on urinary sodium excretion or blood pressure in the
conscious SHR; combined administration of these compounds
resulted in a fivefold increase in sodium excretion and a marked
rise in urinary cGMP excretion but no change in blood pressure
[115]. In conscious DOCA-salt rats, the addition of C-ANP
[4—23] (1 to 10 .g kg' min) to an E-24.11 inhibitor (SQ
28603 or SCH 34826) produced a greater hypotensive response
(ca. 60 mm Hg) and a trend towards a more significant and
prolonged natriuresis [114, 117]. One study has extended ob-
servations in the SHR to examine the effects of chronic dosing
with thiorphan in the presence and absence of C-ANP receptor
ligand [116]. Neither thiorphan (1.5 mg kg .hr) nor SC
46542 (0.1 mg kg hr I) affected blood pressure when given
as a continuous infusion (by an extracorporeal pump) over 10
days; but when co-administered, mean arterial blood pressure
fell by ca. 30 mm Hg by day 3 of the infusion and remained
below baseline for the duration of the study, although an
upward trend was apparent. Interestingly, in the same protocol,
chronic infusion of ANP alone or in combination with thiorphan
and SC 46542 led to a more rapid return of blood pressure to
baseline, within the 10-day experimental period. The authors
interpreted these results as demonstrating tachyphylaxis and
dismissed blood pressure reduction by manipulation of ANP
activity as a therapeutic option. A more recent study, however,
has provided some evidence of benefit from prolonged inhibi-
tion of E-24. 11 in the SHR. Monopoli et at [120] gave SCH
34826 (100 mg kg ') orally twice daily for four weeks and
noted a small but significant reduction in left ventricular weight
when compared with vehicle-treated controls. This effect on
cardiac hypertrophy occurred without any observed change in
blood pressure, although this was measured using the less
sensitive tail-cuff technique rather than by direct arterial mon-
itoring.
Effect of E-24.l1 inhibition on sodium excretion and blood
pressure in humans
The profile of activity of E-24. 11 inhibitors in animals has
prompted a keen interest in their effects in humans. Data are
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now available from several studies in healthy volunteers. Sig-
nificant increases in urinary sodium excretion have been ob-
served but the effects are small (less than 2-fold). Single oral
doses of acetorphan, 100 or 300 mg, given to eight healthy
subjects increased urinary sodium excretion by about one-third
and two-thirds respectively in the period two to eight hours
after ingestion when compared to placebo [92]. Northridge et al
[121] gave three doses of UK 69578 (0.025 to 10mg kg) and
one dose of saline as a 20 minute infusion to 16 volunteers in a
double-blind study; eight-hour cumulative sodium excretion
increased in a dose-dependent manner from 63 mmol after
saline alone to 114 mmol after the highest dose. Richards et al
[91] have studied the effect of oral candoxatril 25 or 50 mg twice
daily for 24 hours in subjects on a standardized diet. Mean
24-hour sodium excretion exceeded placebo by 81 31 and 64
14 mmol with 25 and 50 mg, respectively. In a follow-up
study [93] comparing 25 mg and 100 mg twice daily for four
days, a transient natriuresis was seen with the higher dose on
the first day which was not sustained although a negative
sodium balance (70 21 mmol) was maintained for the rest of
the study. Burnier et al [122] gave SCH 34826(400, 800 and 1600
mg) and placebo by mouth to eight water-loaded subjects on a
high-salt diet. The peak natriuretic effect was observed two
hours after ingestion. Cumulative five-hour sodium excretion
was greater with all three doses of drug compared to placebo
(+ 15.7 7.3 mmol) but only with the two highest doses of 800
mg (+ 26.7 6 mmol) and 1600 mg (+ 30.9 6.8 mmol) did the
changes reach statistical significance.
These natriuretic responses were accompanied by rises in
urinary cyclic GMP excretion but small and often insignificant
increases in urine volume. None of the studies detected a
change in GFR, blood pressure or heart rate. E-24. 11 inhibition
did not significantly affect potassium or uric acid excretion, but
phosphate excretion was increased in the two studies in which
it was measured [91, 122] and one group noted a rise in urinary
calcium excretion [1221. Plasma renin activity and aldosterone
levels have all been reported to fall during treatment with these
drugs, particularly when basal levels were elevated, for exam-
ple by posture [91]. The renal response to E-24. 11 inhibition is
influenced by dietary sodium intake. Singer et al [123] have
given single oral doses (200 mg) of candoxatrilat to patients with
mild hypertension randomized to a high sodium intake (350
mmol day) or a low sodium diet (10 mmol day) in a
crossover study: The cumulative difference in 24-hour sodium
excretion between active and placebo treatment on the low
sodium diet was 17.7 7.9 mmol compared with 98.1 34.1
mmol on the high sodium diet day. Richards et a! [91] comment
that the effects of E-24. 11 inhibition resembles their experience
with low dose ANP in healthy volunteers. These authors have
extended their studies to demonstrate that the renal response to
candoxatril in humans is enhanced by increasing circulating
ANP levels [94]. Volunteers received a two hour infusion of
ANP on the fifth day of dosing with candoxatril, 25 or 100 mg
twice daily, or placebo. The twofold increase in sodium excre-
tion with ANP alone was almost doubled by co-treatment with
candoxatril 100 mg (but not 25 mg). Again no significant
changes in potassium excretion were observed. Similarly there
were no significant effects on GFR, renal blood flow or blood
pressure.
Data on the effects of E-24. 11 inhibitors in the presence of
elevated endogenous ANP levels are still limited, but what little
there is seems encouraging. Northridge et at [121] compared
infusions of UK 69578 (10 to 400 mg) with saline vehicle in six
patients with mild chronic heart failure (NYHA II). Mean
four-hour urinary sodium excretion increased from 17.7 mmol
on placebo to 43.9 mmol on active treatment. There were no
significant changes in blood pressure or heart rate, but pulmo-
nary wedge pressure fell 28% after infusion of the inhibitor with
no such trend apparent after saline. Acute administration of the
orally active derivative candoxatril (UK 79300) in doses of 200
or 400 mg increased plasma ANP up to 2.5-fold at 90 minutes,
but had no significant effect on measurements of left ventricular
hydraulic load [124]. However, a double-blind study of candox-
atril 150 mg or placebo twice daily for 10 days in a similar group
of patients has shown a beneficial reduction in pulmonary
wedge pressure with the active agent [Note added in proof (c)].
Oral dosing with sinorphan has been studied in patients with
more severe cardiac failure (NYHA III or IV). Single doses of
this agent (10 to 40 mg) were observed to produce a small but
variable reduction in diastolic blood pressure (—10 9 mm Hg)
with no fall in systolic pressure or change in heart rate and a
non-significant natriuresis and diuresis [96]. In another study
[97], higher doses (30 to 60 mg three times daily) were given for
two days: No change in heart rate or blood pressure was seen,
but at the highest dose the authors observed a 29% fall in
pulmonary wedge pressure and a 20% fall in plasma renin.
Although E-24. 11 inhibitors have little or no effect on blood
pressure in patients with congestive cardiac failure, useful
hypotensive effects have been recorded in some hypertensive
patients. This apparent anomaly may reflect resistance to the
actions of circulating ANP in heart failure, but it should also be
noted that the doses of E-24. 11 inhibitor used in hypertensive
patients have been higher. Lefrancois et at [125] have reported
an open study with sinorphan in 12 patients with mild to
moderate hypertension (supine diastolic pressure 95 to 115 mm
Hg). The dose was increased gradually over three weeks from
25 to 200 mg twice daily; both systolic and diastolic pressure fell
during treatment, reaching significance compared to baseline
after one week on the highest dose. Since blood pressure may
fall with time on placebo treatment alone, a major weakness of
this study is the lack of a time-controlled placebo group. Bevan
et al [126] have completed a double-blind parallel-group study
of 40 patients (supine diastolic pressure 95 to 115 mm Hg)
randomized to receive candoxatril 200 mg or placebo twice
daily for 28 days. Analysis of the blood pressure response prior
to and up to four hours post-dose on day 28 showed no
significant benefit from candoxatril over placebo except for
systolic blood pressure in the erect posture (median fall 12 vs.
3 mm Hg).
A more convincing hypotensive effect has been demonstrated
by Kosoglou et al [127]. In a double-blind, placebo controlled
trial, 24 Black patients with mild hypertension (ca. 151/104 mm
Hg) were stabilized on a normal sodium diet (150 mmol day 1)
and randomized to receive SCH 34826 400 mg four times daily
or placebo for 14 days. On the E-24. 11 inhibitor mean supine
systolic and diastolic blood pressure were reduced by 16 and 12
mm Hg, respectively, without change in heart rate compared
with 3 and 2.6 mm Hg in the placebo group. The higher
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prevalence of "low-renin hypertension" among Black hyper-
tensives may be pertinent to the greater hypotensive effect of
E-24. 11 inhibition in this study.
Another pathological state in which the use of E-24.1l
inhibitors has been explored is hepatic cirrhosis complicated by
ascites. While there is indisputable sodium and water retention
in this condition, blood volume may be normal or reduced and
plasma ANP levels may be raised or normal. Infusions of
exogenous ANP produce a blunted natriuretic effect, in part
because these patients are sensitive to the fall in blood pressure
that accompanies these infusions. In a double-blind, crossover
protocol, Dussaule et al [981 compared the effect of sinorphan
(30 or 100 mg as a single oral dose) with placebo in 16 patients
with hepatic cirrhosis and persistent ascites. The basal plasma
ANP levels in this group varied from 2.6 to 79 pmol . liter
(mean SEM for control group 7.37 1.78 pmol liter'). A
transient twofold increase in urinary sodium excretion was
observed in the first two hour period following ingestion of the
drug that was not seen after the placebo. This response is rather
small and very similar to that produced in healthy volunteers,
although no such control group was included in this study.
Comparable studies with other E-24. 11 inhibitors would be of
interest.
Mechanism of the natriuretic and hypotensive effects of E-24.11
inhibitors
The favored mechanism by which E-24. 11 inhibitors exert
their renal and cardiovascular effects is by potentiation of the
activity of circulating ANP. Given the relatively broad range of
peptides susceptible to degradation by E-24. 11, this thesis has
to be critically examined.
Several observations atest to the fact that ANP is an impor-
tant mediator of the effects of E-24. 11 inhibition. First, there are
the collective observations that E-24. 11 inhibitors increase
plasma ANP levels and potentiate the biological activity of
infusions of the peptide. Second, the renal and hypotensive
responses to E-24.ll inhibitors are more pronounced where
circulating ANP levels are elevated. Third, the effects of
E-24. 11 inhibitors are accompanied by a rise in urinary cyclic
GMP excretion, a marker of ANP activity 1101]. Fourth, several
groups have shown that the effects of E-24. 11 inhibitors can be
blocked or significantly attenuated by antibodies raised against
ANP [101, 107, 118].
Several authors, however, have observed that the effects of
E-24. 11 inhibitors cannot be explained solely in terms of an
increase in circulating ANP levels. In the A-V fistula rat,
thiorphan produced twice the rise in urinary sodium excretion
produced by pharmacological doses of ANP (1000 ng
kg' min 1) with only a fraction (less than 20%) of the rise in
plasma ANP [101]. Similarly, a dissociation between plasma
ANP levels and the hypotensive response to E-24. 11 inhibitors
has been reported in the DOCA-salt rat [103, 118]. Bolus
administration of the prodrug, SCH 34826 (90 mg kg s.c.)
produced a transient twofold increase in plasma ANP levels in
the first hour but at three hours, when the hypotensive effect of
the inhibitor was maximal, plasma ANP levels did not differ
significantly from the control group [103]. In a follow-up study
[118], administration of the active form, SCH 32615 (30
mg kg i.v.), reduced blood pressure by 31 mm Hg without
change in plasma ANP level while ANP 6 kg1 min1
reduced blood pressure by 22 mm Hg and increased plasma
ANP 8- to 10-fold.
Part of the discrepancy between the response to E-24. 11
inhibitors and the change in plasma ANP concentration is that
increased circulating levels of BNP probably also mediate the
response to these agents, although its precise contribution has
yet to be determined. Nonetheless, it is also likely that in
addition to enhancing the effects of circulating ANP and BNP,
E-24. 11 inhibitors enhance the local effects of these peptides.
Inhibition of E-24. 11 on endothelial cells would act to increase
the local concentration of ANP and BNP to which vascular
smooth muscle is exposed. In the kidney, E-24.11 inhibitors
protect filtered ANP and BNP from degradation at the glomer-
ulus and proximal tubule and allow these peptides to reach
normally inaccessible tubule sites. The renal mechanisms un-
derlying the natriuresis and diuresis produced by these peptides
are unclear but involve actions at both the glomerulus and the
tubule. A striking and consistent finding is the appearance of
increased amounts of immunoreactive ANP in the urine during
E-24. 11 inhibition. The immunoreactive peptide in the urine
co-elutes with ANP-28 on HPLC analysis and is therefore likely
to be biologically active. Two tubule sites may respond to this
increased filtered load of ANP and BNP. One such site is the
inner medullary collecting duct, as guanylate cyclase-linked
receptors for ANP have been demonstrated in this segment of
nephron (as reviewed by Zeidel [128]), although whether these
are located at the luminal or basolateral membrane has not been
determined. Another site which must be considered is the
proximal tubule. Until recently no receptors for ANP had been
demonstrated at this site but mRNA for the guanylate cyclase-
coupled receptor has now been demonstrated using the tech-
nique of reverse transcription-polymerase chain reaction ap-
plied to microdissected proximal tubule segments [129].
Moreover, studies have shown that ANP inhibits the effect of
angiotensin II in this nephron segment [130, 131] and such an
action would explain the marked increase in fractional lithium
excretion seen with E-24. 11 inhibitors.
This discussion does not exclude the possibility that other
factors may contribute either directly or passively to the
biological response to E-24. 11 inhibition. CNP is an obvious
candidate; while this peptide does not circulate, the demonstra-
tion that CNP [59] as well as E-24.11 [34, 35] is expressed by
endothelial cells and the presence of its receptor on vascular
smooth muscle cells suggests the existence of a paracrine
system which can be modulated by inhibition of E-24. 11. Other
candidates which must be considered in the response to E-24. 11
inhibitors are bradykinin, the enkephalins and endothelin. Com-
paring bradykinin with SQ 29,072, Seymour et al [112] found
that doses of bradykinin that reduced blood pressure to a degree
comparable to the E-24. 11 inhibitor in DOCA-salt rats had no
effect on urinary sodium or cyclic GMP excretion. Furthermore
doses of SQ 29,072 that potentiated the effects of ANP had no
effect on the hypotensive response to bradykinin [113]. Con-
versely, Sybertz et a! [103, 118] found no effect of the bradyki-
nm antagonist [Thi5'8-D-Phe7] bradykinin (20 g ' min ')
or the opiate antagonist naltrexone (5 mg kg1 s.c.) on the
hypotensive response to SCH 34826 and SCH 39370, respec-
tively, in DOCA-salt rats. However, Roman et al [132] have
reported that the bradykinin antagonist [D-Arg°, Hyp3, Thi5,
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D-Phe7, Thi8] bradykinin (5 ig min ')inhibits the increase in
renal papillary blood flow produced by phosphoramidon (5.5
kg1 min 1) in anesthetized normotensive rats. Using the
same kinin antagonist (30 tg kg min I), Smits, McGraw
and Trapani [133] completely abolished the rise in sodium
excretion induced by co-administration of thiorphan (30
mg kg)andlow-doseANP(67ng kg min)inanesthe-
tized rats. The effect of the bradykinin antagonist on the
response to the ANP infusion alone was not studied, but the
data argue that kinins, perhaps locally released within the
kidney rather than circulating, may play at least a permissive
role in the effect of E-24. 11 inhibition on ANP-induced natri-
uresis.
Inhibition of endothelin synthesis may participate in the
hypotensive response to some but not all E-24. 11 inhibitors.
Endothelin- 1 (21 amino acids) is generated from a larger inter-
mediate (39 amino acids) hormone, big endothelin-1, by "en-
dothelin converting enzyme (ECE)." Interest in ECE is driven
by the finding that big endothelin exhibits only 1/100th to
1/200th the contractile activity of endothelin-l [134]; thus inhi-
bition of this enzyme would be expected to reduce the biolog-
ical activity of the "endothelin system" and lower blood
pressure. Several studies have shown that phosphoramidon
blocks the pressor response to infused big endothelin-l in
anesthetized rats [134—137], implicating a phosphoramidon-
sensitive enzyme in the conversion of this molecule to the more
active species, endothelin-1. Similarly, SQ 28,603 has been
reported to attenuate the vasoconstrictor effect of big endothe-
lin on the renal, mesenteric and hindquarter vascular beds in
conscious rats [138]. Significantly, however, thiorphan is con-
siderably less active than phosphoramidon in inhibiting the
pressor response to big endothelin and ketatorphan has no
effect on this response [135, 137]. These observations raise the
possibility that ECE is a phosphoramidon-sensitive enzyme
that is not E-24. 11. In addition they indicate a diversity among
the "specific" E-24. 11 inhibitors that might manifest as a
difference in potency in blood pressure reduction; that is, those
E-24. 11 inhibitors that also inhibit ECE might exhibit greater
hypotensive activity.
Clinical potential of E-24.11 inhibitors
E-24. 11 inhibitors appear to have the most to offer in the
management of heart failure, although continued benefit from
chronic administration remains to be demonstrated. Concern
has been expressed at the possibility of tolerance to long-term
treatment with these agents, mediated by down-regulation of
ANP receptors. Against this is the persistent elevation of
urinary cyclic GMP levels in chronic dosing studies [93], but the
question of tolerance needs to be addressed. The efficacy of
E-24. 11 inhibitors in the treatment of hypertension also needs
more rigorous evaluation. The data from animal studies suggest
that the acute effects of these drugs are more marked in
volume-dependent rather than genetic hypertension; thus they
may be of particular value in subgroups of patients with
low-rcnin hypertension. Moreover, they may complement other
antihypertensive treatments prone to activation of the renin-
aldosterone system and sodium and water retention.
In the treatment of these disorders, E-24. 11 inhibitors pose an
interesting challenge to established diuretics. Despite their long
safety record, diuretics are associated with metabolic side
effects which are not without clinical concern. Thus, they cause
hypokalaemia, hyperuricaemia and may raise serum lipids.
Over use can cause serious dehydration with renal impairment.
In contrast, E-24. 11 inhibitors are relatively potassium-sparing
and do not appear to affect uric acid excretion. Given the
dependence of E-24. 11 inhibitors on circulating ANP for their
activity, the risks of dehydration should be negligible: ANP
levels would be expected to fall with successful diuresis,
checking the action of the drug as the needs for its effects
diminish.
In terms of natriuretic potency, E-24. 11 inhibitors resemble
thiazides more closely than loop-diuretics [107, 139]. However,
E-24. 11 inhibitors are more than just diuretics. First, studies in
patients with cardiac failure have shown that these agents
reduce cardiac preload, an effect more pronounced than their
action on afterload [96, 121]. Moreover, ANP has been reported
to reduce pulmonary blood pressure and chronic infusion of the
peptide attenuates pulmonary hypertension and vascular re-
modeling in hypoxic rats [140, 141]. Extrapolating from these
observations, it is possible that E-24. 11 inhibitors may enhance
the action of ANP (and BNP) released from the right heart and
have useful effects on pulmonary vascular resistance in heart
failure. These potential attributes need to be investigated in
humans.
Second, unlike diuretics, E-24. 11 inhibitors antagonize rather
than stimulate the renin-aldosterone system [139]. Indeed, their
actions on the renin-angiotensin-aldosterone system would be
complementary and additive to ACE inhibitors; while ACE
inhibition reduces angiotensin II and lowers aldosterone levels,
E-24. 11 inhibition would reduce renin and further decrease
aldosterone secretion. Conversely, bradykinin levels would be
increased, a factor that may be important for the renal actions
of E-24. 11 inhibitors, as already discussed. Thus the addition of
E-24. 11 inhibitor to ACE inhibitor in the appropriate setting
(that is, raised plasma ANP levels) might be expected to
produce a greater overall vasodilator and natriuretic effect, an
idea supported by recent work in dogs [111]. It should also be
remembered that both ACE inhibitors [142] and E-24.ll inhib-
itors [120] have been reported to reduce cardiac hypertrophy in
experimental animal models, perhaps mediated by inhibition of
the action of angiotensin II. A potential benefit that might
accrue from the chronic use of these two groups of drugs,
therefore, is a more effective reduction in cardiac hypertrophy.
It is reasoning such as this that may lead to the future devel-
opment of so-called mixed inhibitors, tat is, agents such as SQ
29072 (Table 1) that exhibit effective inhibitory activity against
both E-24.ll and ACE.
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Notes added in proof
Seymour et al have now extended their studies to the effect of E-24. 11
inhibition on the response to BNP. Emphasizing the importance of
using the form of BNP homologous to the test species, these authors
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found that SQ 28, 603 enhanced the renal effect and BNP 32 in
cynomolgus monkeys.
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